Furthermore, following the promising data demonstrating that setanaxib could overcome CD8 T exclusion in tumours from preclinical murine models,42 setanaxib is also being tested in combination with immunotherapy in a Phase II clinical trial in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (NCT05323656). This evidence concerns the gene CD8A and metastatic squamous cell carcinoma.